News and Press

The Tyrolean government has approved funding for a new TBE study at the Institute of Virology. The project investigates population immunity and transmission risks in the Zillertal using blood samples, ticks and bulk milk.

Priv.-Doz. Dr. Martin Ludlow from the Research Center for Emerging Infections and Zoonoses at the University of Veterinary Medicine Foundation, Hannover, will hold a talk titled “Challenges and opportunities in the use of contemporary RSV-A and -B strains in the study of virus entry, spread, and immune responses” on October 28, 2026 at 3:00 pm in the Pharmacology Lecture Hall.

Dr. Mathilde Richard from the Department of Viroscience at Erasmus MC, Rotterdam, will give a lecture entitled “Mechanisms of highly pathogenic avian influenza virus emergence” on 29 October 2026 at 3.00 pm in the Pharmacology Lecture Hall.

From 1 October 2026, the Institute of Virology Innsbruck is switching to a new laboratory information system (LIS). Brief delays in result transmission may occur during the introductory phase.

The EU has approved Clesrovimab (Enflonsia®), a third RSV prophylactic antibody alongside Palivizumab and Nirsevimab — offering a fixed 105 mg dose regardless of an infant’s body weight. Clinical trials show efficacy and safety comparable to existing RSV antibodies, with a single dose covering a full RSV season.